Literature DB >> 8567518

During acute hypercapnia vasopressin inhibits an angiotensin drive to ventilation in conscious dogs.

J K Walker1, D B Jennings.   

Abstract

Intravenous infusion of arginine vasopressin (AVP) depresses the slope of the ventilatory response to CO2 during acute hypercapnia. We therefore tested the hypothesis that AVP V1-receptor blockade would increase the slope of the ventilatory response to CO2. After a 20-min control period, an AVP V1-receptor antagonist (d(CH2)5[Tyr(Me)2]AVP) was injected into six conscious resting dogs. Thirty minutes after AVP V1-receptor blockade, dogs were exposed to sequential 20-min periods of 5 and 6.5% inspired CO2 in air. A second protocol (no AVP V1-receptor blockade) was conducted as a control. As predicted, AVP V1-receptor blockade enhanced ventilation during inhalation of 6.5% CO2 in association with an increased metabolic rate and increased plasma angiotensin II (ANG II). In eupneic dogs, stimulation of respiration by AVP V1-receptor blockade is mediated by ANG II. A third protocol with ANG II-receptor blockade (intravenous infusion of saralasin) combined with AVP V1-receptor blockade indicated that ANG II mediated the increase in metabolism and the augmented ventilation during inhalation of 6.5% CO2. We conclude that during acute hypercapnia of sufficient magnitude, and perhaps duration, AVP inhibits an ANG II-mediated stimulation of metabolism and respiration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8567518     DOI: 10.1152/jappl.1995.79.3.786

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  2 in total

1.  Acid-Base Homeostasis During Vasopressin V2 Receptor Antagonist Treatment in Autosomal Dominant Polycystic Kidney Disease Patients.

Authors:  Judith E Heida; Ron T Gansevoort; Esther Meijer
Journal:  Kidney Int Rep       Date:  2021-01-05

Review 2.  Dysregulation of the Renin-Angiotensin System and the Vasopressinergic System Interactions in Cardiovascular Disorders.

Authors:  Ewa Szczepanska-Sadowska; Katarzyna Czarzasta; Agnieszka Cudnoch-Jedrzejewska
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.